Contrasting Expression Pattern of RNA-sensing Receptors TLR7, RIG-I and MDA5 in Interferon-positive and Interferon-negative Patients with Primary Sjögren's Syndrome
Overview
Authors
Affiliations
Objective: The interferon (IFN) type I signature is present in over half of patients with primary Sjögren's syndrome (pSS) and associated with higher disease-activity and autoantibody presence. Plasmacytoid dendritic cells (pDCs) are considered as the main source of enhanced IFN type I expression. The objective of this study was to unravel the molecular pathways underlying IFN type I bioactivity in pDCs of patients with pSS.
Methods: Blood samples from 42 healthy controls (HC) and 115 patients with pSS were stratified according to their IFN type I signature. CD123BDCA4 pDCs and CD14 monocytes were isolated from peripheral blood mononuclear cells (PBMCs). Genome-wide microarray analysis was conducted on sorted pDCs in a small sample set, followed by validation of differentially expressed genes of interest in pDCs and monocytes.
Results: We found an upregulation of endosomal toll-like receptor (TLR) 7, but not TLR9, in IFN-positive (IFNpos) pDCs (p<0.05) and monocytes (p=0.024). Additionally, the downstream signalling molecules MyD88, RSAD2 and IRF7 were upregulated, as were the cytoplasmic RNA-sensing receptors DDX58/retinoic acid inducible gene-I (RIG-I) and IFIH1/melanoma differentiation associated gene-5 (MDA5). In vitro triggering of the TLR7-pathway in HC PBMCs induced upregulation of DDX58/RIG-I and IFIH1/MDA5, and downregulated TLR9. The upregulation of TLR7, its downstream signalling pathway, DDX58/RIG-I and IFIH1/MDA5 were confined to patients with IFN-positive pSS. IFN-negative patients had a contrasting expression pattern-TLR7 normal, and decreased TLR9, RIG-I and MDA5.
Conclusions: Here we conclude a contrasting expression pattern of the RNA-sensing receptors TLR7, RIG-I and MDA5 in pDCs and monocytes of patients with IFNpos pSS. This profile could explain the pathogenic IFN production and might reveal novel therapeutic targets in these patients.
Sex-specific differences in primary Sjögren's disease.
Punnanitinont A, Kramer J Front Dent Med. 2025; 4:1168645.
PMID: 39916928 PMC: 11797869. DOI: 10.3389/fdmed.2023.1168645.
Mechanisms underlying sex differences in autoimmunity.
Fairweather D, Beetler D, McCabe E, Lieberman S J Clin Invest. 2024; 134(18).
PMID: 39286970 PMC: 11405048. DOI: 10.1172/JCI180076.
Xu Y, Han J, Fan Z, Liang S BMC Immunol. 2024; 25(1):53.
PMID: 39080525 PMC: 11287849. DOI: 10.1186/s12865-024-00646-8.
Advances in cellular and molecular pathways of salivary gland damage in Sjögren's syndrome.
Qi W, Tian J, Wang G, Yan Y, Wang T, Wei Y Front Immunol. 2024; 15:1405126.
PMID: 39050857 PMC: 11266040. DOI: 10.3389/fimmu.2024.1405126.
Punnanitinont A, Kasperek E, Zhu C, Yu G, Miecznikowski J, Kramer J J Leukoc Biol. 2023; 115(3):497-510.
PMID: 37930711 PMC: 10990110. DOI: 10.1093/jleuko/qiad135.